Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BROOKLYN IMMUNOTHERAPEUTICS, INC.

(BTX)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about BROOKLYN IMMUNOTHERAPEUTICS, INC.
01/20Brooklyn ImmunoTherapeutics Welcomes Erin S. Enright and Heather B. Redman to Its Board..
GL
01/20Brooklyn ImmunoTherapeutics, Inc. Appoints Erin S. Enright and Heather B. Redman to its..
CI
01/13Brooklyn ImmunoTherapeutics Provides Update on Regenerative Medicine Intellectual Prope..
AQ
2021Cantor Fitzgerald Starts Brooklyn ImmunoTherapeutics at Overweight With $9 Price Target
MT
2021Brooklyn Immunotherapeutics, Inc. Announces Resignation of Luba Greenwood as Director E..
CI
2021Brooklyn ImmunoTherapeutics Added to ICE Biotechnology Index
AQ
2021BROOKLYN IMMUNOTHERAPEUTICS, INC.(NA : BTX) added to NASDAQ Biotechnology Index
CI
2021Brooklyn ImmunoTherapeutics Added toáICE Biotechnology Index
AQ
2021Brooklyn ImmunoTherapeutics Named to Nasdaq Biotechnology Index
AQ
2021Brooklyn ImmunoTherapeutics to Present at Two Upcoming December Conferences
AQ
2021Brooklyn ImmunoTherapeutics Welcomes Susan McClatchey as Vice President and Head of Qua..
GL
2021Brooklyn ImmunoTherapeutics, Inc. Appoints Susan McClatchey as Head of Quality
CI
2021Brooklyn ImmunoTherapeutics Plans Secondary Offering Of 6.28 Million Shares
MT
2021Brooklyn ImmunoTherapeutics Announces Filing of Registration Statement for Proposed Sec..
AQ
2021Earnings Flash (BTX) BROOKLYN IMMUNOTHERAPEUTICS LLC Posts Q3 Loss $-1.70
MT
2021BROOKLYN IMMUNOTHERAPEUTICS, INC.(NA : BTX) added to NASDAQ Composite Index
CI
2021BROOKLYN IMMUNOTHERAPEUTICS : to Transfer Share Listing to Nasdaq From NYSE American
MT
2021BROOKLYN IMMUNOTHERAPEUTICS : to Move Stock Exchange Listing to Nasdaq - Form 8-K
PU
2021BROOKLYN IMMUNOTHERAPEUTICS : to Move Stock Exchange Listing to Nasdaq
AQ
2021BROOKLYN IMMUNOTHERAPEUTICS : Maxim Starts Brooklyn ImmunoTherapeutics at Buy with $20 Pri..
MT
2021BROOKLYN IMMUNOTHERAPEUTICS : Provides Highlights of Shareholder Update Call from Septembe..
PU
2021Brooklyn ImmunoTherapeutics ReportsáInducement Grants
GL
2021BROOKLYN IMMUNOTHERAPEUTICS : Names Roger Sidhu Chief Medical Officer
MT
2021BROOKLYN IMMUNOTHERAPEUTICS : Provides Highlights of Shareholder Update
AQ
2021Brooklyn ImmunoTherapeutics Appoints Roger Sidhu, M.D. as Chief Medical Officer
GL
2021Brooklyn ImmunoTherapeutics, Inc. Appoints Roger Sidhu as Chief Medical Officer
CI
2021Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from Septemb..
GL
2021BROOKLYN IMMUNOTHERAPEUTICS, INC.(NY : BTX) added to S&P Global BMI Index
CI
2021BROOKLYN IMMUNOTHERAPEUTICS TO CONDU : 30 pm et
AQ
2021BROOKLYN IMMUNOTHERAPEUTICS : RESTATED 2020 STOCK INCENTIVE PLAN (Form 8-K)
PU
2021BROOKLYN IMMUNOTHERAPEUTICS : to Participate in Grand Opening of Cambridge-Based mRNA Clea..
AQ
2021BROOKLYN IMMUNOTHERAPEUTICS : SNN Network Summer Virtual Event Presentation
PU
2021BROOKLYN IMMUNOTHERAPEUTICS : Announces Adjournment of Annual Meeting of Stockholders Due ..
PU
2021BROOKLYN IMMUNOTHERAPEUTICS : Announces Adjournment of Annual Meeting of Stockholders Due ..
AQ
2021Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from August ..
GL
2021BROOKLYN IMMUNOTHERAPEUTICS : Announces Second Quarter 2021 Financial Results (Form 8-K)
PU
2021BROOKLYN IMMUNOTHERAPEUTICS TO CONDU : 30 pm et
AQ
2021BROOKLYN IMMUNOTHERAPEUTICS TO CONDU : 30 pm et
GL
2021BROOKLYN IMMUNOTHERAPEUTICS : Q2 Loss Widens
MT
2021BROOKLYN IMMUNOTHERAPEUTICS : Earnings Flash (BTX) BROOKLYN IMMUNOTHERAPEUTICS LLC Reports..
MT
2021Brooklyn ImmunoTherapeutics Announces Second Quarter 2021 Financial Results
GL
2021Brooklyn ImmunoTherapeutics, Inc. Reports Unaudited Consolidated Earnings Results for t..
CI
2021Brooklyn ImmunoTherapeutics to Present at the SNN Virtual Investor Conference on August..
GL
2021BROOKLYN IMMUNOTHERAPEUTICS : Immuno Reports Inducement Grants
AQ
2021BROOKLYN IMMUNOTHERAPEUTICS : Next Generation Personalized Medicines
PU
2021BROOKLYN IMMUNOTHERAPEUTICS : Welcomes Jay Sial as Chief Administrative Officer (Form 8-K)
PU
2021BROOKLYN IMMUNOTHERAPEUTICS : Acquisition Advances Transformation Into Platform Company Fo..
PU
2021BROOKLYN IMMUNOTHERAPEUTICS : Completes Acquisition of Novellus Therapeutics
AQ
2021Brooklyn ImmunoTherapeutics, Inc. completed the acquisition of Novellus Therapeutics Li..
CI
2021BROOKLYN IMMUNOTHERAPEUTICS : Welcomes Jay Sial as Chief Administrative Officer
PU
2021BROOKLYN IMMUNOTHERAPEUTICS : Welcomes Jay Sial as Chief Administrative Officer
AQ
2021Brooklyn Immunotherapeutics, Inc. Announces Appointment of Jay Sial as Its Chief Admini..
CI
2021BROOKLYN IMMUNOTHERAPEUTICS : Completes Acquisition of Novellus Therapeutics
PU
2021BROOKLYN IMMUNOTHERAPEUTICS : to Present at the Access to Giving Virtual Investor Conferen..
AQ
2021Brooklyn ImmunoTherapeutics Reports Inducement Grants
GL
2021BROOKLYN IMMUNOTHERAPEUTICS : Initial Insider Trading Report (SEC Filing - 3)
PU
2021BROOKLYN IMMUNOTHERAPEUTICS : Insider Selling at Brooklyn Immunotherapeutics (BTX) is Sign..
MT
2021INSIDER TRENDS : Selling By Insiders Lingers at Brooklyn Immunotherapeutics
MT
2021BROOKLYN IMMUNOTHERAPEUTICS : EXECUTIVE EMPLOYMENT AGREEMENT (Form 8-K)
PU
2021BROOKLYN IMMUNOTHERAPEUTICS : Executes Letter of Intent to Buy Novellus Therapeutics
PU
2021BROOKLYN IMMUNOTHERAPEUTICS : Signs Non-Binding Letter of Intent to Buy Novellus Therapeut..
MT
2021BROOKLYN IMMUNOTHERAPEUTICS : Executes Letter of Intent to Acquire Novellus Therapeutics
AQ
2021Brooklyn ImmunoTherapeutics, Inc. signed a non-binding letter of intent to acquire Nove..
CI
2021BROOKLYN IMMUNOTHERAPEUTICS : Welcomes Dr. Kevin A. D'Amour as Chief Scientific Officer (F..
PU
2021BROOKLYN IMMUNOTHERAPEUTICS : to Be Included in the Russell 3000 Index
MT
2021Brooklyn ImmunoTherapeutics Set to Join Russell 3000 Index
GL
2021BROOKLYN IMMUNOTHERAPEUTICS : Welcomes Dr. Kevin A. D'Amour as Chief Scientific Officer
AQ
2021Brooklyn ImmunoTherapeutics, Inc. Welcomes Kevin A. D’Amour as Chief Scientific Officer
CI
2021BROOKLYN IMMUNOTHERAPEUTICS : Sets Up Massachusetts Facility to Pursue Gene Editing, Cellu..
MT
2021BROOKLYN IMMUNOTHERAPEUTICS : Establishes Research and Development Center in Cambridge, Ma..
AQ
2021Brooklyn ImmunoTherapeutics Establishes Research and Development Center in Cambridge, M..
CI
2021BROOKLYN IMMUNOTHERAPEUTICS : To Sell Up To $40 Million in Common Shares to Lincoln Park C..
MT
2021BROOKLYN IMMUNOTHERAPEUTICS : Purchase and Registration Rights Agreements (Form 8-K)
PU
2021BROOKLYN IMMUNOTHERAPEUTICS : CEO Howard J. Federoff Provides Roadmap for the Company's Fu..
BU
2021BROOKLYN IMMUNOTHERAPEUTICS : Strengthens Investment in Licensed mRNA Technology Platform ..
PU
1  2Next